^
Association details:
| Biomarker: | HER-2 H878Y |
|---|---|
| Cancer: | Hepatocellular Cancer |
| Drug: | lapatinib (EGFR inhibitor, HER2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Differential Sensitivity of ERBB2 Kinase Domain Mutations towards Lapatinib
Excerpt:
...ERBB2-H878Y mutant had the highest sensitivity against lapatinib among all mutations tested with a cellular IC50 value nearly half to that of wild type ERBB2….Moreover, an ERBB2 mutant (H878Y) observed in 11% of hepatocellular carcinoma patients showed remarkable sensitivity to lapatinib indicating that lapatinib may be an attractive option in the future for hepatoma patients with ERBB2-H878Y.
DOI:
10.1371/journal.pone.0026760
